Sub Filer Id
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15 (d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): October 18, 2006
SIGA
TECHNOLOGIES, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
0-23047
|
13-3864870
|
|
(State
or other jurisdiction of
incorporation
or organization)
|
(Commission
file number)
|
(I.R.S.
employer
identification
no.)
|
|
420
Lexington Avenue, Suite 408
New
York, New York
(Address
of principal executive offices)
|
|
10170
(Zip
code)
|
Registrant’s
telephone number, including area code: (212) 672-9100
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
r
Written
communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
r
Soliciting
material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
r
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
r
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01. Other
Events.
On
October 18, 2006, SIGA Technologies, Inc. (“SIGA”) announced that its lead drug,
SIGA-246, is the first drug ever to demonstrate 100% protection against human
smallpox virus in a primate trial conducted at the federal Centers for Disease
Control and Prevention (“CDC”). In this study, once-daily, oral administration
of SIGA-246 protected cynomolgus monkeys from smallpox disease following
intravenous high dosing with smallpox virus. The drug prevented symptoms of
disease whether delivered at the same time as the virus or 24 hours later,
supporting the drug’s use for both post-exposure prophylaxis and treatment.
SIGA-246 completely prevented lesion formation and reduced viral load to
non-threatening levels in treated animals with no obvious toxicity. The study
was conducted under rigorous bio-safety and -security conditions at the World
Health Organization Collaborating Centers for Smallpox and Other Poxvirus
Infections’ BSL-4 laboratory located at the CDC in Atlanta and was funded by the
Department of Health and Human Services, the CDC and the Department of Defense’s
Defense Threat Reduction Agency under the supervision of Dr. John Huggins,
Chief
of the Viral Therapeutics Branch, U.S. Army Medical Research Institute of
Infectious Diseases.
On
October 18, 2006, SIGA issued a press release announcing the above described
results. A copy of the press release is attached hereto as Exhibit
99.1.
Item
9.01. Financial Statements and Exhibits.
(c)
Exhibits
|
Exhibit
No.
|
Description
|
|
99.1
|
Press
Release dated October 18, 2006.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
SIGA
TECHNOLOGIES,
INC.
By:
/s/
Thomas N.
Konatich
Name:
Thomas
N.
Konatich
Title: Acting
Chief Executive Officer & Chief
Financial
Officer
Date: October
18, 2006